Similar articles for PMID: 24079290

Year	Number of Results
1986	1
1992	1
1997	1
1999	1
2001	2
2002	1
2003	1
2004	3
2005	4
2006	3
2007	2
2008	1
2009	4
2010	4
2011	11
2012	5
2013	13
2014	13
2015	9
2016	6
2017	7
2018	13
2019	8
2020	4
2021	10
2022	14
2023	4
2024	0

1

High-density lipoproteins: a consensus statement from the National Lipid Association.

Toth PP, Barter PJ, Rosenson RS, Boden WE, Chapman MJ, Cuchel M, D'Agostino RB Sr, Davidson MH, Davidson WS, Heinecke JW, Karas RH, Kontush A, Krauss RM, Miller M, Rader DJ. Toth PP, et al. J Clin Lipidol. 2013 Sep-Oct;7(5):484-525. doi: 10.1016/j.jacl.2013.08.001. Epub 2013 Aug 11. J Clin Lipidol. 2013. PMID: 24079290 Review.

2

Should low high-density lipoprotein cholesterol (HDL-C) be treated?

Toth PP, Barylski M, Nikolic D, Rizzo M, Montalto G, Banach M. Toth PP, et al. Best Pract Res Clin Endocrinol Metab. 2014 Jun;28(3):353-68. doi: 10.1016/j.beem.2013.11.002. Epub 2013 Nov 15. Best Pract Res Clin Endocrinol Metab. 2014. PMID: 24840264 Review.

3

Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.

Rosenblit PD. Rosenblit PD. Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y. Curr Diab Rep. 2019. PMID: 31754844 Review.

4

High-density lipoprotein as a therapeutic target: a systematic review.

Singh IM, Shishehbor MH, Ansell BJ. Singh IM, et al. JAMA. 2007 Aug 15;298(7):786-98. doi: 10.1001/jama.298.7.786. JAMA. 2007. PMID: 17699012 Review.

5

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL. Cziraky MJ, et al. J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. J Manag Care Pharm. 2008. PMID: 19891279 Review.

6

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C; European Consensus Panel on HDL-C. Chapman MJ, et al. Curr Med Res Opin. 2004 Aug;20(8):1253-68. doi: 10.1185/030079904125004402. Curr Med Res Opin. 2004. PMID: 15324528 Review.

7

High-density lipoproteins in the prevention of cardiovascular disease: changing the paradigm.

Tuteja S, Rader DJ. Tuteja S, et al. Clin Pharmacol Ther. 2014 Jul;96(1):48-56. doi: 10.1038/clpt.2014.79. Epub 2014 Apr 8. Clin Pharmacol Ther. 2014. PMID: 24713591 Review.

8

Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein.

Kon V, Yang H, Fazio S. Kon V, et al. Arch Med Res. 2015 Jul;46(5):379-91. doi: 10.1016/j.arcmed.2015.05.009. Epub 2015 May 23. Arch Med Res. 2015. PMID: 26009251 Free PMC article. Review.

9

Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).

Khera AV, Demler OV, Adelman SJ, Collins HL, Glynn RJ, Ridker PM, Rader DJ, Mora S. Khera AV, et al. Circulation. 2017 Jun 20;135(25):2494-2504. doi: 10.1161/CIRCULATIONAHA.116.025678. Epub 2017 Apr 27. Circulation. 2017. PMID: 28450350 Free PMC article. Clinical Trial.

10

Novel therapies focused on the high-density lipoprotein particle.

van Capelleveen JC, Brewer HB, Kastelein JJ, Hovingh GK. van Capelleveen JC, et al. Circ Res. 2014 Jan 3;114(1):193-204. doi: 10.1161/CIRCRESAHA.114.301804. Circ Res. 2014. PMID: 24385512 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

129 results

Results by year